Dr Liz Caldon

Liz studies the way that faulty DNA replication and cell divisions can alter the fate of a cancer cell. She received undergraduate degrees in Science and Law from UNSW Sydney, before studying towards a Masters of Science at the University of Toronto, Canada.  Her PhD studies took her back to Sydney
Group Leader - Replication and Genome Stability

Conjoint/Adjunct Role(s)

Conjoint Senior Lecturer, School of Medical Sciences, UNSW Sydney

Liz studies the way that faulty DNA replication and cell divisions can alter the fate of a cancer cell. She received undergraduate degrees in Science and Law from UNSW Sydney, before studying towards a Masters of Science at the University of Toronto, Canada.  Her PhD studies took her back to Sydney where she investigated the interaction between hormone signalling and proliferative control of breast cancer cells.  In 2013 she established her own research team at the Garvan Institute, the Replication and Genome Stability Group.

The Replication and Genome Stability group works towards understanding the way that cancer cells evolve due to the selective pressure of therapeutic drugs and cancer driver genes called oncogenes. A primary goal is understanding the evolution of hormone therapy resistance in breast cancer, which is a major cause of breast cancer related death.  Based on their findings on the multistep acquisition of hormone therapy resistance, Liz and her team are focussed on translating knowledge about fundamental breast cancer biology and evolution into targetable therapies that provide clinical benefit.

Research Interests

Breast cancer
Ovarian cancer
DNA damage
Hormone signalling in cancer
Genomic instability

Awards and Honours

2018 - The Ridley Ken Davies Award
2017 - Heliflite Young Explorer Award
2017-2020 National Breast Cancer Foundation Career Development Fellowship
2015 - CHAMP Private Equity Young Pioneer Award
2014 - Cancer Institute Career Development Fellowship
2013 - Cure Cancer Conference and Professional Development Grant
2013 - “Best Translational Research Presentation”, Lowy Cancer Symposium, UNSW, Sydney, Australia
2011-2016 - National Breast Cancer Foundation Postdoctoral Fellowship
2011 - Cure Cancer Australia Postdoctoral Fellowship
2010 - Young Garvan Fellowship
2009 - Qantas Research Travel Award
2005-2007 - Cancer Institute NSW Scholar
2004 - Beth Yarrow Scholarship
2003 - LH Ainsworth Scholarship in Cancer Research
2002 - Connaught Graduate Fellowship, University of Toronto

Education

2007 - PhD, University of NSW, Sydney - Australia
2003 - MSc University of Toronto - Canada
2001 - Bachelor of Laws (LLB), University of New South Wales, Sydney - Australia
1998 - BSc (Hons, University Medal) University of New South Wales, Sydney - Australia

Selected Publications

 

James RW Conway, Sean C Warren, David Herrmann, Kendelle J Murphy, Aurélie S Cazet, Claire Vennin, Robert F Shearer, Monica J Killen, Astrid Magenau, Pauline Mélénec, Mark Pinese, Max Nobis, Anaiis Zaratzian, Alice Boulghourjian, Andrew M Da Silva, Gonzalo del Monte-Nieto, Arne SA Adam, Richard P Harvey, Jody J Haigh, Yingxiao Wang, David R Croucher, Owen J Sansom, Marina Pajic, C Elizabeth Caldon, Jennifer P Morton*, Paul Timpson*. (2018) Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Cell reports 23 (11), 3312-3326

Rogers S, Fey D, McCloy RA, Parker BL, Mitchell NJ, Payne RJ, Daly RJ, James DE, Caldon CE, Watkins DN, Croucher DR, Burgess A. PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. J Cell Sci. 2016;129(7):1340-54.

Caldon C. Cdk2 regulates metastasis suppressor BRMS1. Cell Cycle. 2016;15(6):779-80.

Rogers, S., Gloss, B., Lee, C., Sergio, C., Dinger, M., Musgrove, E., Burgess, A., Caldon, C. (2015). Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division, 10(1), 1.

Loh SF, Cooper C, Selinger CI, Barnes EH, Chan C, Carmalt H, R West, L Gluch, JM Beith, C.E. Caldon, S. O'Toole (2014) Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast. Journal of Clinical Pathology

C.E. Caldon (2014) Estrogen signaling and the DNA damage response in hormone dependent breast cancers Frontiers in Oncology 4:106.

A. Stone, M.J. Cowley, F. Valdes-Mora, R.A. McCloy, C.M. Sergio, D. Gallego-Ortega, C.E. Caldon, C.J. Ormandy, A.V. Biankin, J.M. Gee, R.I. Nicholson, C.G. Print, S.J. Clark, E.A. Musgrove. (2013) BCL-2 hypermethylation is a potential biomarker of sensitivity to anti-mitotic chemotherapy in endocrine-resistant breast cancer. Molecular Cancer Therapeutics. 12(9), 1874-1885.

Caldon C.E., C.M. Sergio, A. Burgess, A.J. Deans, R.L. Sutherland, E.A. Musgrove. (2013). “Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1” Cell Cycle. 12(4):606-17.

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.

Caldon C.E., C.M. Sergio, R.L. Sutherland, E.A. Musgrove. (2013). “Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells” Cell Cycle. 12(4):596-605.

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.­­

Kalyuga M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, C.E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, C.J. Ormandy. (2012) “ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.” PLoS Biol. 10(12):e1001461.

Caldon, C. E., C. M. Sergio, J. Kang, A. Muthukaruppan, M. N. Boersma, A. Stone, J. Barraclough, C. S. Lee, M. A. Black, L. D. Miller, J. M. Gee, R. I. Nicholson, R. L. Sutherland, C. G. Print and E. A. Musgrove (2012). "Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells." Molecular Cancer Therapeutics 11(7): 1488-1499.

Musgrove, E. A., C. E. Caldon, J. Barraclough, A. Stone and R. L. Sutherland (2011). "Cyclin D as a therapeutic target in cancer." Nature Reviews Cancer 11(8): 558-572.

Caldon, C. E., R. L. Sutherland and E. A. Musgrove (2010). "Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer." Cell Cycle 9: 10.

Caldon, C. E. and E. A. Musgrove (2010). "Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer." Cell Division 5(2).

Caldon, C. E., C. M. Sergio, J. Schutte, M. N. Boersma, R. L. Sutherland, J. S. Carroll and E. A. Musgrove (2009). "Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc." Molecular and Cellular Biology 29(17): 4623-4639.

Caldon, C. E., A. Swarbrick, C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini." Cancer Research 68(8): 3026-3036.

Caldon, C. E., C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation." Oncogene 27(1): 126-138.

Butt, A. J., C. E. Caldon, C. M. McNeil, A. Swarbrick, E. A. Musgrove and R. L. Sutherland (2008). "Cell cycle machinery: links with genesis and treatment of breast cancer." Advances in Experimental Medicine and Biology 630: 189-205.

Caldon, C. E., R. J. Daly, R. L. Sutherland and E. A. Musgrove (2006). "Cell cycle control in breast cancer cells." Journal of Cellular Biochemistry 97(2): 261-274.